Navigation Links
New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
Date:11/21/2008

nical experience have not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly, and it may be useful to assess renal function in these patients prior to initiating dosing and periodically thereafter.

Additional Information about JANUVIA

In controlled clinical studies as both monotherapy and combination therapy with metformin or pioglitazone, the overall incidences of adverse reactions, hypoglycemia, and discontinuation of therapy due to clinical adverse reactions with JANUVIA were similar to placebo. In these clinical studies, the most common adverse reactions reported with JANUVIA (e 5 percent and higher than placebo) were stuffy or runny nose and sore throat, upper respiratory infection and headache. In clinical trials in combination with a sulfonylurea (glimepiride), with or without metformin, JANUVIA demonstrated an overall incidence of adverse reactions higher than that seen with placebo, in part related to a higher incidence of hypoglycemia.

In a pre-specified pooled analysis of two monotherapy studies, an add-on to metformin study, and an add-on to pioglitazone study, the overall incidence of adverse reactions of hypoglycemia in patients treated with JANUVIA 100 mg was similar to placebo (1.2 percent vs. 0.9 percent). Adverse reactions of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required. In an additional, 24-week, placebo-controlled factorial study of initial therapy with sitagliptin in combination with metformin, the incidence of hypoglycemia was 0.6 percent in patients given placebo, 0.6 percent in patients given sitagliptin alone, 0.8 percent in patients given metformin alone and 1.6 perce
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
2. Landmark study defines benefits of early HIV testing and treatment for infected infants
3. Study identifies causes of bone loss in breast cancer survivors
4. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
5. Study Suggests Need for More Aggressive Outpatient Monitoring of Patients Hearts When Cause of Stroke is Unclear
6. Rutgers researchers study cites media violence as critical risk factor for aggression
7. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
8. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
9. New Study Finds CO2 Ablative Fractional Resurfacing Safe And Effective For Deep Acne Scarring
10. Study investigates Gore-tex-type device to stop strokes and mini-strokes
11. The smart way to study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 
(Date:7/27/2015)... ... July 28, 2015 , ... Dr. Robert G. Schwartz ... practice has teamed up with Realief Neuropathy Centers in order to offer his patients ... the signs and symptoms of peripheral neuropathy. , Peripheral neuropathy is a disease caused ...
(Date:7/27/2015)... ... July 27, 2015 , ... Specific cardiovascular risk factors, ... brain volumes that may be early indicators of Alzheimer’s disease and dementia, according ... that vascular risk factors damage the brain and can result in cognitive impairment,” ...
(Date:7/27/2015)... Madre, CA (PRWEB) , ... July 27, 2015 ... ... of healthcare today, especially in wound center management. Earlier this year Wound ... wound care education and training for WCA wound centers. Customized learning paths ...
(Date:7/27/2015)... Los Angeles, CA (PRWEB) , ... July 27, 2015 , ... ... See the Derm for 7 Common Skin Issues,” describes common skin issues such as ... the technology available for cosmetic dermatologists to treat them. The treatment options listed include ...
(Date:7/27/2015)... ... July 27, 2015 , ... Send ... and mobile collaboration, announced today the latest software release for ... and other feature enhancements. , This software release gives the widely used online ...
Breaking Medicine News(10 mins):Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 3Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 3Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2
... a key molecule that controls the growth, spread and survival ... toward new and better treatment options for pancreatic cancer . ... Beta molecule plays in pancreatic cancer and that they have ... and survival through its effect on NF Kappa B -- ...
... the drug alendronate (Fosamax) can reduce the risk of vertebral ... not osteoporosis. 3,737 postmenopausal women between ages 55 and 80 ... -2.5 were evaluated . About half the women randomly received ... thereafter while the other half took a placebo. ,The ...
... its growth factors aren’t just produced in the pancreas, but ... areas of the brain//, the result can be brain cell ... people with Alzheimer’s. ,The research was conducted in rats, ... IGF I and IGF II were produced in the nerve ...
... well known that HIV patients are at an increased risk ... study shows // aggressive antiretroviral therapy may help lower that ... antiretroviral therapy was associated with a lower incidence of Kaposi ... on more than 7,300 patients infected with HIV and the ...
... Intravenous administration of the drug tezosentan did not improve worsening ... failure // despite high hopes. The above fact was found ... to date. The study was conducted to evaluate if something ... order to speed up hospital discharge and prevent them from ...
... that how much we drink may be decided by a ... gene called DRD2 Taq1A(C32806T) polymorphism and social alcohol drinking may ... stronger gene of this type will tend to drink alcohol ... The gene is responsible for enhancing the pleasure that is ...
Cached Medicine News:
(Date:7/27/2015)... Mass. , July 27, 2015 ... of Merck KGaA of Darmstadt, ... with celares GmbH to provide pegylation services to ... service offering enabled by the collaboration includes feasibility ... milligram to gram quantities required for pilot and ...
(Date:7/27/2015)... , July 27, 2015  Endo International plc (NASDAQ: ... 2015 financial results before the open of the U.S. financial ... management team will host a conference call and webcast at ... number to access the call is U.S./ Canada ... is 93183256. Please dial in 10 minutes prior to the ...
(Date:7/27/2015)... PITTSBURGH , July 27, 2015  Mylan N.V. ... regarding Teva,s (NYSE and TASE: TEVA) announcement of its ... and its withdrawal of its unsolicited expression of interest ... Robert J. Coury stated: "We congratulate Teva on ... their continued, and potentially enhanced, commitment to the generics ...
Breaking Medicine Technology:EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH 2EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH 3Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 2Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 3Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 4Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 5Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 6Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 7Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 8Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 9
... Safety Profile of the Intramuscular Formulation,of Peramivir ... BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ --,BioCryst ... I,clinical studies of an intramuscular (i.m.) formulation ... of Influenza Conference in,Toronto, Ontario, Canada. This ...
... 70 abstracts highlight VELCADE efficacy in broad range,of ... Mass., June 19, 2007 /PRNewswire-FirstCall/ --,Millennium Pharmaceuticals, Inc. ... therapy with unsurpassed single-agent,efficacy for patients with previously ... upcoming International Myeloma,Workshop (IMW) in Kos, Greece, June ...
Cached Medicine Technology:BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 2BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 3BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 4BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 5BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8
... camera system for high resolution photomicrography. The ... of the highest color fidelity, resolution and ... expect perfect images due to many unique ... innovative readout modes. The Leica DFC480 is ...
This compact photomicrographic system assures simple operation to achieve the exposure accuracy required for sophisticated photomicrography in most research and clinical environments....
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Stat Stain is ideal for stat, routine ... blood smears (10-15 seconds) and bone marrow ... finely dispersed stain particles which yield excellent ... many of the steps involved in the ...
Medicine Products: